LKT Labs

Biochemicals for Life Science Research

Saracatinib

Saracatinib

Product ID S0168
Cas No. 379231-04-6
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $45.00 In stock
5 mg $68.00 In stock
25 mg $225.00 In stock
Bulk Quote

Quicklinks

Description

Saracatinib is an inhibitor of Src and Abl family kinases that is used for its anticancer chemotherapeutic and immunomodulatory benefits. Saracatinib is currently in clinical trials as a potential treatment for a variety of cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, and myeloma. In cellular and animal models, this compound inhibits migration, invasion, and growth of cancer cells. Additionally, saracatinib displays mixed immunomodulatory effects, decreasing T cell cytokine production in one in vitro model and increasing CD8+ memory T cells and production of IFN-γ in another in vitro model.

Product Info

Cas No.

379231-04-6
Purity

≥98%
Formula

C27H32ClN5O5
Formula Wt.

542.03
Chemical Name

N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
IUPAC Name

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(oxan-4-yloxy)quinazolin-4-amine
Synonym

AZD-0530
Appearance

Off white powder

Shipping and Storage

Store Temp

Ambient
Ship Temp

Ambient

Downloads

MSDS

S0168 MSDS PDF
Info Sheet

S0168 Info Sheet PDF

References

Gangadhar TC, Clark JI, Karrison T, et al. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma. Invest New Drugs. 2013 Jun;31(3):769-73. PMID: 23151808.

Nam HJ, Im SA, Oh DY, et al. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer. Mol Cancer Ther. 2013 Jan;12(1):16-26. PMID: 23144237.

Cavalloni G, Peraldo-Neia C, Sarotto I, et al. Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas. Mol Cancer Ther. 2012 Jul;11(7):1528-38. PMID: 22452946.

Takai S, Sabzevari H, Farsaci B, et al. Distinct effects of saracatinib on memory CD8+ T cell differentiation. J Immunol. 2012 May 1;188(9):4323-33. PMID: 22450814.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • S9755

    (R)-Synephrine

    Synephrine is an endogenous alkaloid.

    ≥98%
  • T3350

    Timolol Maleate

    β-adrenergic antagonist.

    ≥98%
  • J0240

    JAK2 Inhibitor V

    JAK2 inhibitor.

    ≥98%
  • I5203

    Inauhzin

    p53 activator, IMPDH and SIRT1 inhibitor.

    ≥98%
  • O5212

    Ondansetron Hydrochloride Dihydrate

    5-HT3 antagonist.

    ≥98%
  • M3377

    Mitomycin C

    Alkaloid produced by Streptomyces, DNA cross-li...

    ≥98%
  • A6922

    Arformoterol Tartrate

    R,R enantiomer of formoterol; β2-adrenergic an...

    ≥98%
  • P0370

    Paromomycin Sulfate

    Aminoglycoside; protein translation inhibitor, ...

    ≥98%
  • C0044

    CAL101

    p110δ PI3K inhibitor.

    ≥99%
  • P3540

    PIK-75 Hydrochloride

    p110α PI3K inhibitor.

    ≥98%
  • C0171

    Carboplatin

    Pt-based DNA cross-linker.

    ≥99%
  • N344786

    N-Nitroso Valsartan Methyl Ester

    Valsartan impurity

    ≥98%
  • D3209

    Diclofenac Sodium

    NSAID; COX-1/2 inhibitor, potential K+ channel ...

    ≥99%
  • E9418

    Exendin 3 (9-39)

    Peptide, GLP-1 analog found in Heloderma; GLP-1...

    ≥95%
  • A1319

    Adenosine Triphosphate Disodium Hydrate

    Endogenous coenzyme, unit of cellular energy, r...

    ≥95%
  • I0933

    Icilin

    TRPM8 activator, TRPV3 blocker.

    ≥98%
  • A4924

    AMG-208

    c-MET and Ron inhibitor.

    ≥98%
  • A9801

    Azaperone

    Butyrophenone; α-adrenergic, D2, histamine ant...

    ≥98%
  • V9200

    VX-950

    NS3/4A serine protease inhibitor.

    ≥98%
  • T6834

    Triacsin C

    Acyl-CoA synthetase inhibitor.

    ≥95%